U.S. Markets closed

Infusion Therapy Firm BioScrip to Buy Rival Option Care

M. Corey Goldman

agreed to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S. On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.